|Bid||77.57 x 200|
|Ask||77.60 x 200|
|Day's Range||77.14 - 78.00|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2018|
|Forward Dividend & Yield||2.25 (2.87%)|
|1y Target Est||90.90|
The FDA approved the drug, which is sold in the U.S. under the brand name Tymlos, in April 2017.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting LLY. Over the last one-month, outflows of investor capital in ETFs holding LLY totaled $3.13 billion.
CVS Health tapped a former Eli Lilly finance chief to run its pharmacy benefit business as the drugstore giant works to complete an acquisition of insurer Aetna.
Drugstore operator chain CVS Health Corp said it had hired former Eli Lilly Chief Financial Officer Derica Rice as the president of its pharmacy benefit management business. CVS is in the process of closing ...
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) generates revenues from collaboration agreements through which it receives product sales revenues, royalties, license fees, milestone payments, and contract research payments. In fiscal 2017, Nektar Therapeutics generated total revenues of $307.7 million compared with $165.4 million in fiscal 2016.
Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.
Let's see if Eli Lilly and Company (LLY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.